Last Updated : November 22, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Retevmo | selpercatinib | Thyroid cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Revatio | Sildenafil citrate | Pulmonary arterial hypertension (WHO class II and III) | List in a similar manner | Complete | ||
Revestive | teduglutide | Short Bowel Syndrome (SBS), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
Revestive | Teduglutide | Short bowel syndrome | Reimburse with clinical criteria and/or conditions | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (+bortezomib+dex) | Reimburse with clinical criteria and/or conditions | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma (as maintenance therapy) | Reimburse with clinical criteria and/or conditions | Complete | ||
Revlimid | Lenalidomide | Multiple Myeloma, newly diagnosed | Reimburse with clinical criteria and/or conditions | Complete | ||
Revolade | Eltrombopag olamine | Chronic immune thrombocytopenic purpura | Do not list | Complete | ||
Revolade | Eltrombopag | Thrombocytopenia associated with chronic hepatitis c infection | List with criteria/condition | Complete | ||
Revolade | eltrombopag | Severe aplastic anemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Rexulti | Brexpiprazole | schizophrenia | Reimburse with clinical criteria and/or conditions | Complete | ||
Reyataz | Atazanavir | HIV infection | List in a similar manner to other drugs in class | Complete | ||
Rezurock | belumosudil | Graft-versus-host disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | Psoriatic Arthritis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | atopic dermatitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | ankylosing spondylitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Rinvoq | upadacitinib | Crohns disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
Rituxan | Rituximab | Granulomatosis with polyangiitis and microscopic polyangiitis | List with clinical criteria and/or conditions | Complete | ||
Rituxan | Rituximab | Acute Lymphoblastic Leukemia | Do not reimburse | Complete | ||
Rosiver | Ivermectin | Rosacea | List with criteria/condition | Complete | ||
Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete |